New findings about the sugary armor on the brain’s frontline cells could shed light on cognitive decline and diseases like Alzheimer’s—and open new avenues for treatment.
This week on the podcast, Stanford psychiatry professor Erin Gibson joins us again to share the latest findings on sleep, myelin, and neurodegenerative disease.
With Knight Initiative support, Stanford researchers uncover a biochemical “off-ramp” in ketosis, rewriting our understanding of how ketosis influences metabolism.
This week on From Our Neurons to Yours, we talk with Stanford neurologist Mike Greicius about his critique of new amyloid-clearing Alzheimer's drugs, and his optimism for the next wave of therapies currently in development.
A team of neuroscientists at the Knight Initiative for Brain Resilience have zeroed in on a critical regulator of brain metabolism that may be over-activated in the brains of patients with Alzheimer’s disease.
Pro-inflammatory protein TREM1 in peripheral immune cells may promote age-related cognitive decline and dementia, according to Knight Initiative–funded research.
Recent research supported by the Knight Initiative has identified a link between lipid droplets in the microglia to a known genetic risk factor for AD.
Two new studies supported by the Knight Initiative highlight groundbreaking new early biomarkers for the diagnosis and treatment of neurodegenerative disease.
This week, we sit down with neuroscientist Tony Wyss-Coray to learn about how some of your organs may be aging faster than the rest of you.
This week on From Our Neurons to Yours, we sit down with Stanford neurologist Kathleen Poston to learn about a sea change in our understanding of Parkinson's Disease.